menu
    • menu

    Company profile for Pharvaris

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule brad...
    Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PharvarisSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Grafenauweg 8 CH-6300 Zug
    Telephone
    Telephone
    +1-646-942-5630
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pharvaris.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharvaris to Present Clinical Data at AAAAI 2026 Annual Meeting
    Pharvaris to Present Clinical Data at AAAAI 2026 Annual Meeting

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235142/0/en/Pharvaris-to-Present-Clinical-Data-at-the-AAAAI-2026-Annual-Meeting.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Pharvaris Outlines 2026 Strategic Priorities
    Pharvaris Outlines 2026 Strategic Priorities

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216675/0/en/Pharvaris-Outlines-2026-Strategic-Priorities.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Pharvaris Reports Deucrictibant's Efficacy In HAE Attack
    Pharvaris Reports Deucrictibant's Efficacy In HAE Attack

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198720/0/en/Pharvaris-Announces-Positive-Topline-Data-from-RAPIDe-3-Pivotal-Study-Confirming-Potential-of-Deucrictibant-for-On-Demand-Treatment-of-HAE-Attacks.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Pharvaris To Present Clinical Data At ACAAI 2025 Conference
    Pharvaris To Present Clinical Data At ACAAI 2025 Conference

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171859/0/en/Pharvaris-to-Present-Clinical-Data-at-the-ACAAI-2025-Annual-Scientific-Meeting.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    Pharvaris Announces Q2 2025 Financial Results and Business Update
    Pharvaris Announces Q2 2025 Financial Results and Business Update

    12 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/12/3132128/0/en/Pharvaris-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    12 Aug 2025
    Share Share
    Pharvaris Closes $201.2M Upsized Public Offering
    Pharvaris Closes $201.2M Upsized Public Offering

    24 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/24/3121449/0/en/Pharvaris-Announces-Closing-of-201-2-Million-Upsized-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shar.html

    GLOBENEWSWIRE
    24 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search